"In silico technologies also enable drug developers to perform, in theory, an unlimited number of tests using a wide range of variables that include age, sex, and the health status of each member of the virtual patient pool, compared to the more restrictive parameters of a traditional trial. By reducing the amount of trial and error involved in collecting data, drug developers can focus on therapies that prove to be more effective in treating a specific group of patients."

Tanja Dowe is a health care executive.

She shares her story and discusses her KevinMD article, "The promise of in silico drug development to improve patient outcomes."

Did you enjoy today's episode?

Rate and review the show so more audiences can find The Podcast by KevinMD.

Subscribe on your favorite podcast app to get notified when a new episode comes out.

Click here to earn 1.0 AMA PRA Category 1 CME for this episode.

Also available in Category 1 CME bundles.

Powered by CMEfy - a seamless way for busy clinician learners to discover Internet Point-of-Care Learning opportunities that reward AMA PRA Category 1 Credit(s)™. Learn more at about.cmefy.com/cme-info

How in silico drug development can improve patient outcomes